Sept 12- Pfizer Inc and India's Ranbaxy Laboratories Ltd on Friday won dismissal of an antitrust lawsuit accusing them of conspiring to delay sales of generic versions of the cholesterol drug Lipitor, the best-selling drug in history.» Read More
I always prefer it when pharmaceutical/biotech execs and analysts can break out of their scientific/financial jargon and give good soundbites or quotes. So, among the flurry of research notes I've received over the weekend and this morning on the Genentech Avastin news the award goes to Rodman & Renshaw's Mike King who writes, "The biotech leader has its groove back."
A drug made by Genentech received federal approval on Friday to treat breast cancer, a decision that could represent a major shift in standards for assessing the effectiveness of cancer medicines.
Shortly before the closing bell trading in shares of Genentech was halted for news pending. Then, right after the bell the company issued this press release announcing the Food and Drug Administration has granted "accelerated approval" to Genentech's Avastin for use on breast cancer.
As we sit here closely monitoring the wires and waiting for word out of Genentech and/or the FDA about a decision on Avastin for breast cancer, it seemed like as good a time as any to once again post some samples of a flood of recent emails from readers--the good, the bad and the ugly.
The results of the controversial study called "Enhance" of the cholesterol drug Vytorin from Merck and Schering-Plough will not be presented as a prestigious "late breaker" at the upcoming annual meeting of the American College of Cardiology.
Who needs Oscar ballots? Biotech investing wonks/nerds (and I'm not suggesting I am one) might wanna start an office pool about when and what the FDA's decision will be on Genentech's drug Avastin for breast cancer.
Perhaps this item belongs in the "Funny Business" blog of my witty colleague Jane Wells, but when I saw this headline cross the Dow Jones Newswire this afternoon under the "Market Talk" blurb they move several times during the trading day, I just had to throw it up on my blog. I didn't know DJ had hired "Linda Richman" to write copy, or maybe Mike Myers needs a little extra income.
The world's biggest drug company is spending chump change to take out a little biotech at a 118 percent premium. Pfizer, which has a cash hoard of more than $20 billion, is plunking down a paltry (for Pfizer, that is) $195 million in cash money to buy Encysive Pharmaceuticals.
Almost exactly one year since Onyx Pharmaceuticals announced positive results of its drug Nexavar for liver cancer and the stock doubled in one day, the biopharmaceutical company is providing an example of the ups and downs of drug development and biotech investing.
European markets were firmly in positive territory Monday, as banking stocks gained following news Northern Rock was to be nationalized. Oil-related firms also jumped as crude prices neared one-month highs.
Even though I'm off today I, like a lot of folks, couldn't help checking my landline voicemail at work. And much to my surprise one of the messages was from Mark Gottlieb, the Chief Compliance Officer at Visium Asset Mgt. I referred to him in yesterday's post.
Taking an extra day off to extend the long weekend before we go into a very busy period. Possibly a week from today (Friday) Genentech could get word from the Food and Drug Administration on its cancer drug Avastin for breast cancer. The agency could approve it, reject it or delay making a decision.
Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Early today a press release and headlines were crossing the wires about Dendreon announcing positive test results on its controversial prostate cancer drug, Provenge, at an oncology conference in San Francisco.
This morning we did back-to-back interviews on "Squawk Box" with the author of the New York Magazine article about his experience on the smoking cessation drug Chantix and a Pfizer exec to respond to it. You can watch the segment in the video clip.
Not long after I submitted my last post I got word that the House Energy and Commerce Committee sent a letter today to the four Congressmen who had requested a hearing into the Dendreon/Provenge saga. And the answer is "no." The stock, which had been rallying on heavy volume today, sank when we broke the news on "Closing Bell."
There was a mini-rally and spike in volume in shares of good ol' Dendreon this morning and early afternoon. The run-up occured ahead of CEO Dr. Mitchell Gold's presentation at the BIO CEO conference in New York City at 1:15 ET.
In a CNBC and Mad Money exclusive, Cramer sat down with Schering-Plough CEO Fred Hassan for his first interview since the controversy over the effectiveness of the cholesterol drug Vytorin. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
After the closing bell yesterday Genentech popped out a stock-moving press release. The world's most highly-valued biotech announced that its drug Avastin when used in combo with Sanofi-Aventis' chemo drug, Taxotere, helped women with a certain type of aggressive, advanced breast cancer live longer without the disease getting worse.
Digital camera and medical equipment maker Fujifilm Holdings said on Wednesday it will spend up to 155 billion yen ($1.45 billion) to take control of drug maker Toyama Chemical to grow in the pharmaceuticals market.